The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
The future of JAK inhibition in myelofibrosis
Featured:
Jean-Jacques Kiladjian
John Mascarenhas
Stefan N. Constantinescu
Tiziano Barbui
Claire Harrison
Haifa Kathrin Al-AliDuring the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in myelofibrosis. The session was chaired by John Mascarenhas and involved an analysis from Claire Harrison, Haifa Kathrin Al-Ali, Tiziano Barbui, Jean-Jacques Kiladjian, and Stefan N. Constantinescu.
The future of JAK inhibition in myelofibrosis
Key topics of discussion included: “How to select appropriate JAK inhibitors in patients with myelofibrosis (MF)”; “What patient subsets a JAK inhibitor may capture”; and “The future of JAK inhibitors in treating myelofibrosis, and whether this type of inhibitor will exist as a single agent or in combination therapy at initiation.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?